The heterogeneity of cell type may directly lead to the heterogeneity of metabolism in different parts of the same tumor; for example, the clear cells in ccRCC should respond to angiogenesis and glycolysis inhibitors, while eosinophilic components in ccRCC may benefit from mTOR or glutaminase inhibition [61]. The gene discussed is GLS; the disease is nonpapillary renal cell carcinoma.